Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

• High medical need for Shigella vaccine
• Over 250 million infections worldwide annually
• Vaccine was well tolerated and induced a significant increase in functional antibodies
• Data published in prestigious journal The Lancet Infectious Diseases

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns,…

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our…

• New website and branding
• Matches Intravacc’s aspiration to become a leading vaccine CDMO
• We welcome your feedback on our new website